Dr. Shirley Seo earned her doctorate degree in Pharmaceutics from The University of Texas at Austin. Upon graduation in 2004, she began her FDA career by joining the Office of Generic Drugs as a reviewer in the Division of Bioequivalence.
Dr. Seo joined the Office of Clinical Pharmacology (OCP) in 2007 as a primary reviewer. She is now a team leader for antiviral drug products in the Office of Clinical Pharmacology. During her time in OCP, she has been heavily involved in IND and NDA analysis and review, interpreting regulations, and providing guidance on numerous drug development programs for antiviral drug products. Her main areas of interest include, pediatrics, products for medical countermeasures, and drug interactions.
